In the latest trading session, 0.41 million Lucid Diagnostics Inc (NASDAQ:LUCD) shares changed hands as the company’s beta touched 1.36. With the company’s most recent per share price at $1.41 changed hands at -$0.01 or -0.35% at last look, the market valuation stands at $83.97M. LUCD’s current price is a discount, trading about -15.6% off its 52-week high of $1.63. The share price had its 52-week low at $0.63, which suggests the last value was 55.32% up since then.
Analysts gave the Lucid Diagnostics Inc (LUCD) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 1 out of 3 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended LUCD as a Hold, 2 felt it is a Buy and 0 rated the stock as Underweight. Lucid Diagnostics Inc’s EPS for the current quarter is expected to be -0.15.
Lucid Diagnostics Inc (NASDAQ:LUCD) trade information
Instantly LUCD was in red as seen in intraday trades today. With action -11.01%, the performance over the past five days has been red. The company’s shares are showing year-to-date upside of 72.83%, with the 5-day performance at -11.01% in the red. However, in the 30-day time frame, Lucid Diagnostics Inc (NASDAQ:LUCD) is 59.44% up.
The consensus price target for the stock as assigned by Wall Street analysts is 2.5, meaning bulls need an upside of 43.6% from its recent market value. According to analyst projections, LUCD’s forecast low is 2.5 with 2.5 as the target high. To hit the forecast high, the stock’s price needs a -77.3% plunge from its current level, while the stock would need to soar -77.3% for it to hit the projected low.
Lucid Diagnostics Inc (LUCD) estimates and forecasts
Year-over-year growth is forecast to reach 88.04% up from the last financial year.
Consensus estimates given by 6 financial analysts project the company’s revenue in the current quarter to hit an average of 1.42M. 5 analysts are of the opinion that Lucid Diagnostics Inc’s revenue for the current quarter will be 1.61M. The company’s revenue for the corresponding quarters a year ago was 1.04M and 1M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 36.95%. The estimates for the next quarter sales put growth at 61.32%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -110.66%. The 2025 estimates are for Lucid Diagnostics Inc earnings to increase by 84.60%, but the outlook for the next 5-year period is at 58.74% per year.
Lucid Diagnostics Inc (NASDAQ:LUCD)’s Major holders
VANGUARD GROUP INC holds the second largest percentage of outstanding shares, with 1.2461% or 0.56 million shares worth $0.46 million as of 2024-06-30.
Among Mutual Funds, the top two as of Sep 30, 2024 were Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund. With 366.92 shares estimated at $0.52 million under it, the former controlled 0.62% of total outstanding shares. On the other hand, Vanguard Extended Market Index Fund held about 0.33% of the shares, roughly 193.99 shares worth around $0.28 million.
